Is Anuh Pharma overvalued or undervalued?

Jun 09 2025 04:09 PM IST
share
Share Via
As of April 8, 2025, Anuh Pharma's valuation has shifted to attractive, with a PE ratio of 22.36, an EV to EBITDA of 16.77, and a ROCE of 23.53%, indicating it is fairly valued compared to peers despite a recent 1-year return of -4.51% against the Sensex's 7.60%.
As of 8 April 2025, Anuh Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in its perceived investment quality. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 22.36, an EV to EBITDA of 16.77, and a ROCE of 23.53%.

In comparison to its peers, Anuh Pharma's PE ratio is in line with the industry average, while its EV to EBITDA is also competitive. Notable peers include a company with a PE of 22.5 and another with an EV to EBITDA of 17.0. Despite recent underperformance against the Sensex, with a 1-year return of -4.51% compared to the Sensex's 7.60%, the company's strong fundamentals suggest it is positioned well within the pharmaceuticals and biotechnology sector.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read